Nobel Prize-Winning Economist Alvin Roth on Organ Markets

Key Takeaways

• 130,000 US kidney failures occur annually, costing Medicare $55 B
• Only ~30,000 transplants performed in 2025 versus 90,000 waitlist
• Legal kidney sales could add ~70,000 kidneys yearly, saving lives
• Market incentives may improve donor screening and reduce dialysis expenses
• Government subsidies could fund kidneys for low‑income patients, lowering costs

Pulse Analysis

The United States faces a chronic kidney‑failure crisis, with more than 130,000 new cases each year and Medicare shouldering over $55 billion in dialysis costs. Despite this burden, only about 30,000 transplants were performed in 2025 while roughly 90,000 patients sit on the national waiting list. The resulting shortage forces many into long‑term dialysis, a treatment that diminishes quality of life and carries a high mortality rate. Alvin Roth’s recent op‑ed brings renewed attention to the economic dimensions of this public‑health emergency, arguing that a regulated organ market could bridge the gap.

Economic theory suggests that introducing price signals into kidney donation would align incentives for both donors and recipients. By compensating donors, the market could attract an additional 70,000 kidneys annually, enough to meet current demand and reduce reliance on costly dialysis. Such a system would also encourage rigorous medical screening, as providers would face liability for substandard organs. Critics worry about exploitation of the poor, but Roth proposes safeguards—strict eligibility criteria, transparent pricing, and oversight—to prevent coercion. Moreover, insurance plans could cover purchases, ensuring that wealth alone does not dictate access, while targeted government subsidies could protect low‑income patients.

Policy reform would require amending the 1984 National Organ Transplant Act, which bans “valuable consideration” for organs. Legislators could look to regulated markets for blood or gamete donation as models for oversight. If implemented, the shift could lower overall healthcare expenditures, accelerate patients’ return to the workforce, and reduce the annual death toll of roughly 40,000 patients who die while waiting. The debate now hinges on balancing ethical concerns with the tangible benefits of a market‑driven solution, a conversation that Roth’s stature helps elevate within both economic and medical circles.